KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $11.5 billion.

  • Novartis Ag's Cash & Equivalents changed 0.0% to $11.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $11.5 billion, marking a year-over-year change of 0.0%. This contributed to the annual value of $11.5 billion for FY2025, which is 0.0% changed from last year.
  • Novartis Ag's Cash & Equivalents amounted to $11.5 billion in Q4 2025, which was down 0.0% from $9.6 billion recorded in Q3 2025.
  • Over the past 5 years, Novartis Ag's Cash & Equivalents peaked at $6000.0 billion during Q1 2021, and registered a low of $70.0 million during Q1 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $9.5 billion (2024), whereas its average is $308.5 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 789463684.21% in 2021, then crashed by 9999.88% in 2022.
  • Novartis Ag's Cash & Equivalents (Quarter) stood at $12.4 billion in 2021, then plummeted by 39.41% to $7.5 billion in 2022, then changed by 0.0% to $7.5 billion in 2023, then soared by 52.44% to $11.5 billion in 2024, then changed by 0.0% to $11.5 billion in 2025.
  • Its last three reported values are $11.5 billion in Q4 2025, $9.6 billion for Q3 2025, and $6.7 billion during Q2 2025.